The influence of cilostazol on learning and memory, and cyclin D1 expression in the cerebral cortex of rats with chronic cerebral ischemia were investigated. A chronic cerebral ischemia model was established using the permanent bilateral common carotid artery occlusion method (2VO), learning and memory capacity was detected using the Morris water maze, and expression changes in apoptosis regulating gene cyclin D1 were tested by RT-PCR. Results of the Morris water maze indicated that significant extensions were found in the escape latent period and swimming path of rats in the ischemia group (2VO group), learning and memory results in the cilostazol group was obviously superior compared to the 2VO group (P<0.05), and the expression of cyclin D1 was observed to increase in both the ischemia and cilostazol intervention groups at the 9th week of ischemia. A significant difference was observed, compared with the sham operation group (P<0.05), the expression level decreased in the ischemia group compared with the cilostazol group, and a significant difference was identified compared with the ischemia group (P<0.05). Cilostazol can reduce nerve function impairment and improve learning and memory functions by affecting changes in apoptosis regulating genes.

Department of Internal Medicine Neurology Jilin Central Hospital Jilin China

See more in PubMed

CHOI JM, SHIN HK, KIM KY, LEE JH, HONG KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther. 2002;300:787–793. doi: 10.1124/jpet.300.3.787. PubMed DOI

COPANI A, UBERTI D, SORTINO MA, BRUNO V, NICOLETTI F, MEMO M. Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends Neurosci. 2001;24:25–31. doi: 10.1016/S0166-2236(00)01663-5. PubMed DOI

HONDA F, IMAI H, ISHIKAWA M, KUBOTA C, SHIMIZU T, FUKUNAGA M, SAITO N. Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke. 2006;37:223–238. doi: 10.1161/01.STR.0000196977.76702.6d. PubMed DOI

LEE JH, PARK SY, SHIN YW, HONG KW, KIM CD, SUNG SM, KIM KY, LEE WS. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 2006;1082:182–191. doi: 10.1016/j.brainres.2006.01.088. PubMed DOI

O’BRIEN JT. Vascular Cognitive Impairment. Am J Geriatr Psychiatry. 2006;14:724–733. doi: 10.1097/01.JGP.0000231780.44684.7e. PubMed DOI

PARK SY, LEE JH, KIM CD, LEE WS, PARK WS, HAN J, KWAK YG, KIM KY, HONG KW. Cilostazol suppresses superoxide production and expression of adhesion moleculesole in human endothelial cells via medliation of cAMP- depedent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther. 2006;317:1238–1245. doi: 10.1124/jpet.105.098509. PubMed DOI

YUZAWA I, YAMADA M, FUJII K. An oral administration of cilostazol before focal ischemia reduces the infarct volume with delayed cerebral blood flow increase in rats. J Stroke Cerebrovasc Dis. 2008;17:281–286. doi: 10.1016/j.jstrokecerebrovasdis.2008.03.007. PubMed DOI

ZHAO J, HARADA N, KURIHARA H, NAKAGATA N, OKAJIMA K. Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-1 in the hippocampus. Neuropharmacology. 2010;58:774–783. doi: 10.1016/j.neuropharm.2009.12.008. PubMed DOI